Nikhil Munshi, MD
Enriched profileDirector of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center; Kraft Family Chair; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Nikhil Munshi is Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center; Kraft Family Chair; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,801 publications with 104,230 citations (h-index 152); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Nikhil Munshi as a Highly Cited Researcher (Clinical Medicine, 2020; Cross-Field, 2021).
Data verified 7 Sept 2026
Overview
Updated 14 Oct 2026
Nikhil Munshi, MD, is Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Boston, MA. The public record shows 1,801 publications with 104,230 citations (h-index 152), centered on Multiple Myeloma. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 13 companies, 8 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Sponsor: Travera Inc
- Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
Sponsor: Boston VA Research Institute, Inc.
- Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Sponsor: Boston VA Research Institute, Inc.
Industry payments
Updated 14 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202510 payments$12,530openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20258 payments$11,591openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Thalidomide Analog78.5%Revlimid55%Pomalyst45%Part D≥20 patientsProteasome Inhibitor21.5%Ninlaro100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
8 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- Multiscale functional characterization of genomic variation in human developmental disorders
Ut Southwestern Medical Center
FY2026$1,748,385UM1HG011996 - Decoding regulatory variants in cardiovascular disease
Boston University (charles River Campus)
FY2026$849,790R01HL181047
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Nature medicine
Article2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.
Journal of clinical oncology
Article2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Nikhil-C-Munshi-39747674
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/NikhilMunshiMD
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_nikhil-c-munshi-md-activity-6584403982771384320-se-z
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Apple Podcasts
podcasts.apple.com/gb/podcast/nikhil-c-munshi-md-raising-the-bcma-standard-in/id208201754
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Other
myeloma.org/people/nikhil-munshi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗ - Other
myelomasociety.org/officers/nikhil-c-munshi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Immediate Past President
International Myeloma Society (founding member and former Vice President)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Member
Scientific Advisory Board, International Myeloma Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗ - Associate Director
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- Robert A. Kyle Lifetime Achievement Award (Waldenström's Award)
International Myeloma Society, most distinguished lifetime achievement honor in myeloma research
2013verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Lifetime Achievement Award
Association of VA Hematologists and Oncologists
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Secondary affiliations
appointments beyond the home institution- Attending Physician
VA Boston Healthcare System
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bumc.bu.edu ↗ - Senior Physician
Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - Adjunct Associate Professor
Boston University Chobanian & Avedisian School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bumc.bu.edu ↗
Media & interviews
press, podcasts and appearances- JCO Article Insights podcast
discussing IMS-IMWG Consensus Recommendations on Definition of High-Risk Multiple Myeloma
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
- Video interview
VJHemOnc, on genomic instability, immunotherapy and molecular manipulation in multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens